SEC2, a major histocompatibility complex class II (MHC II)-dependent T-cell mitogen, binds
MHC II and T-cell receptor (TCR) Vβs to induce effective co-stimulating signals for clonal T …

Redirecting CD8 T cell immunity with self/tumor-specific affinity-matured T cell receptors
(TCRs) is a promising approach for clinical adoptive T cell therapy, with the aim to improve …

In previous studies, we have shown that Th2 cell differentiation is diminished but Th1 cell
differentiation is increased in Stat5a-deficient (Stat5a−/−) CD4+ T cells. In the present study …

Recent data show that TCR/CD3 stimulation induces activation of Stat5 in murine T cells.
Here, we show that CD3 ligation by mAb and Staphylococcal enterotoxin (SE) induce a …

Adoptive cell therapy with T-cell receptor (TCR)-engineered T cells represents a powerful
method to redirect the immune system against tumours. However, although TCR recognition …

ABSTRACT CD7 is a cell-surface molecule, expressed on T lymphocytes and NK cells,
which functions as a costimulatory receptor for T cell proliferation. SECTM1 has been …

Summary We found IL-6-STAT3 pathway suppresses MHC class II (MHCII) expression on
dendritic cells (DCs) and attenuates T cell activation. Here, we showed that IL-6-STAT3 …

The tuberous sclerosis complex 1 (TSC1) is a tumor suppressor that inhibits the mammalian
target of rapamycin (mTOR), which serves as a key regulator of inflammatory responses after …

T helper (Th) cell differentiation is a key event to mount an appropriate immune response.
Th1 and Th2 cells produce their signature cytokines IFN-γ and IL-4, respectively. However …

As a member of superantigens, Staphylococcal Enterotoxin C2 (SEC2) can potently activate
T cells expressing specific Vβ repertoires and has been applied in clinic for tumor …